The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan's assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 mil...
Novan, Inc. (NASDAQ:NOVN ) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President & Chief Executive Officer John Donofrio - Executive ...
DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, Ma...
DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2022 financial results on Thursday, Ma...
Presentation with live webcast today, March 14th at 10:40 AM ET Presentation with live webcast today, March 14th at 10:40 AM ET...
Live video webcast on Thursday, January 19th at 12:00 PM ET Live video webcast on Thursday, January 19th at 12:00 PM ET...
SAN DIEGO--( BUSINESS WIRE )--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Novan, Inc. (Nasdaq: NOVN) has submitted a New Drug Application (NDA) to the U.S. Food and D...
Novan, Inc. (NASDAQ:NOVN ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President, and Chief Executive Officer John Gay - Chief F...
Novan, Inc. (NASDAQ:NOVN ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Paula Stafford - President, CEO & Chairwoman John Gay - CFO & Corporate Secretary John Donof...